Department of Surgery, Mayo Clinic, Jacksonville, Florida.
Department of Surgery, Mayo Clinic, Jacksonville, Florida.
Surg Obes Relat Dis. 2021 Jul;17(7):1317-1326. doi: 10.1016/j.soard.2021.03.006. Epub 2021 Mar 19.
Chronic kidney disease (CKD) independently increases the risk of 30-day adverse outcomes following metabolic and bariatric surgery (MBS). However, no studies have evaluated the stage of CKD at which increased perioperative risk is manifested. Here, we correlate 30-day major morbidities after MBS with extent of renal disease based on CKD Stage.
To determine the impact of CKD stage on perioperative outcomes after bariatric surgery.
Academic Hospital.
From the 2017 Metabolic and Bariatric Surgery Quality Improvement Program (MBSAQIP) database, we identified patients with CKD who underwent sleeve gastrectomy or laparoscopic gastric bypass surgery. Glomerular filtration rates (GFRs) were calculated and cohorts were generated based on CKD Stage. Complication rates and rates of morbidity and mortality were compared between stages, and strengths of correlation were calculated.
GFR and CKD Stage were calculated for 150,283 patients. There was a significant increase in the risk of major morbidity at each progressive stage of CKD (P < .001 for all compared stages). There was a strong positive linear correlation between increasing CKD Stage and total morbidity (r = .983), including reoperation ( r = .784), readmission (r = .936), unplanned ICU transfer (r = .853), and aggregate complications such as pulmonary (r = .900), bleeding (r = .878), or progressive worsening of renal function (r = .845). In logistic regression, for every 10-point decrease in GFR, odds of total morbidity increased by 6%.
An increased risk of perioperative complications may be seen in early stages of CKD, and risk is compounded in more advanced stages. Bariatric surgical candidates should be counseled on their increased risk of surgical complications even with mild CKD, and the benefits of bariatric surgery should be carefully weighed against significantly increased risks of complications in severe CKD.
慢性肾脏病(CKD)独立增加代谢和减重手术(MBS)后 30 天不良结局的风险。然而,尚无研究评估 CKD 进展至何种阶段时表现出围手术期风险增加。本研究根据 CKD 分期,将 MBS 后 30 天主要并发症与肾脏疾病的严重程度相关联。
确定 CKD 分期对减重手术后围手术期结局的影响。
学术医院。
我们从 2017 年代谢和减重手术质量改进计划(MBSAQIP)数据库中,确定了接受袖状胃切除术或腹腔镜胃旁路手术的 CKD 患者。计算肾小球滤过率(GFR),并根据 CKD 分期生成队列。比较各分期之间的并发症发生率、发病率和死亡率,并计算相关性强度。
为 150283 例患者计算了 GFR 和 CKD 分期。随着 CKD 分期的逐渐进展,主要并发症的风险显著增加(所有比较分期均 P <.001)。随着 CKD 分期的增加,总发病率呈强正线性相关(r =.983),包括再次手术( r =.784)、再入院(r =.936)、非计划性 ICU 转科(r =.853)以及肺部( r =.900)、出血( r =.878)或肾功能进行性恶化等并发症的综合发生率( r =.845)。在逻辑回归中,GFR 每降低 10 分,总发病率的几率增加 6%。
CKD 早期可能会出现围手术期并发症风险增加,并且随着疾病的进展风险会进一步增加。即使患有轻度 CKD,减重手术的候选者也应被告知手术并发症的风险增加,并且在严重 CKD 中,应权衡减重手术的益处与并发症风险显著增加之间的利弊。